The website trilo.bio is the official brand launchpad, product portal, and technical showcase for Trilobio, a deep-tech biotechnology and robotics startup headquartered in San Francisco. Founded by Forbes 30 Under 30 honorees Roya Amini-Naieni and Maximilian Schommer and backed by over $11 million in venture funding from premier investors like Initialized Capital and Lowercarbon Capital, the company is on a mission to completely phase out the manual “pipette era.” The platform serves as an exceptional case study for digital curators looking at how cutting-edge hardware-as-a-service (HaaS) and scientific software products present deep-tech breakthroughs through highly digestible, conversion-ready web interfaces.
The frontend architecture abandons standard medical software grids, neatly unpacking the brand’s unified ecosystem across its core components: the Trilobot benchtop robotic arm, its interchangeable tool rack (featuring automated liquid-handling pipettes and micro-grippers), and Trilobio OS. The interface masterfully showcases how their open-API, plug-and-play architecture connects hardware with software—allowing research fleets to scale up instantly by simply snapping multiple Trilobots together. It spotlights how the platform completely solves the scientific community’s massive reproducibility crisis by letting researchers write protocols at a “biology-level” that can be compiled, shared, and executed on any fleet configuration around the globe.
The user interface delivers a highly polished look that mirrors the precision of an advanced laboratory twin simulation, utilizing clean layouts, sharp display typography, and smooth kinetic micro-interactions. By integrating explicit real-world validation data from active biotechnology deployments like Abalone Bio and Triton Bio—which highlight immediate 25% to 33% increases in sample testing throughput—the landing page provides digital product curators, deep-tech founders, and growth teams with a flawless look into how generative, AI-ready hardware platforms are redefining the boundaries of biological discovery.
